A scientific morning related to gout disease and its prevalence in Iran and the world was held on December 24, 1401 in the department of Firouzgar Hospital in Tehran by Kimiara Company.
In this meeting, Dr. Rahimi, the scientific consultant of the group, explained the treatment protocol according to the latest rheumatology guidelines and the review of strong and effective treatments, including febuxostat.
This scientific morning with the presence of respected rheumatology professors:
- Dear Mr. Dr. Hadi Pourmoqim
- Mrs. Dr. Shahrazad Rahmani
- Mrs. Dr. Lily Azizi
- and internal residents were held on Thursday, 24 Azar 1401.
At the end of this meeting, respected professors commented on the comparison of the efficacy and safety of febuxostat molecule and its superiority over allopurinol in different gout patients.
Also, the bioequivalence studies of febuxostat molecule of Febix brand of Kimiaara company with Adenoric brand of Menarini company were investigated, and the results show that Febix brand is therapeutically equivalent to the main brand of febuxostat of Menarini company according to the bioequivalence criteria approved by FDA.
